---
schema_version: "secwatch.filing_event.v1"
accession: "0001411685-25-000017"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:11:34.080806+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vistagen reports Q3 FY2025 net loss $14.1M; fasedienol Phase 3 progressing

## Summary
- Net loss $14.1M for Q3 ended Dec 31, 2024, vs $6.4M YoY; R&D expense rose to $11.3M from $4.5M.
- Cash and marketable securities $88.6M as of Dec 31, 2024.
- Fasedienol PALISADE-3 and PALISADE-4 Phase 3 trials for SAD ongoing; top-line results expected later 2025.
- Positive exploratory Phase 2A results for PH284 in cancer cachexia announced.
- IND-enabling program for PH80 for menopausal hot flashes continuing; Phase 2B planning for itruvone in MDD.

## SEC filing metadata
- accession: 0001411685-25-000017
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000017/0001411685-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000017/vtgn-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411685-25-000017
- JSON: https://secwatch.observer/filing/0001411685-25-000017.json
- Plain text: https://secwatch.observer/filing/0001411685-25-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.